ReviewDisease models & mechanisms2018
Molecular biomarkers of Alzheimer's disease: progress and prospects.
Review in Disease models & mechanisms, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05020626 (Modelling Tau Deposition and Distribution From Diffusion Tensor Imaging With Generative Adversarial Network for Alzheimer's Disease Diagnosis), which is not on this map. Cited by 97 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Modelling Tau Deposition and Distribution From Diffusion Tensor Imaging With Generative Adversarial Network for Alzheimer's Disease Diagnosis
Who cites it
97 citing papers in PubMed, 2 syntheses or guidelines pooled it, 229 citations in OpenAlex.
- Blood and CSF chemokines in Alzheimer's disease and mild cognitive impairment: a systematic review and meta-analysis.Alzheimer's research & therapy · 2023Pooled it
- Systematic Review: microRNAs as Potential Biomarkers in Mild Cognitive Impairment Diagnosis.Frontiers in aging neuroscience · 2021Pooled it
- CLIC1 Protein Accumulates in Circulating Monocyte Membrane during Neurodegeneration.International journal of molecular sciences · 2020Trial
- Microglia-derived extracellular vesicle content as a biomarker for early detection of Alzheimer's disease.Translational neurodegeneration · 2026Review
- Vitamin DInternational journal of molecular sciences · 2026Article
- Article
- Insights into Biomarkers of Alzheimer's Disease: From Core Markers to Emerging Directions.Aging and disease · 2025Review
- c-Triadem: A constrained, explainable deep learning model to identify novel biomarkers in Alzheimer's disease.PloS one · 2025Article
- Analysis of the Relationship Between NLRP3 and Alzheimer's Disease in Oligodendrocytes based on Bioinformatics andCurrent Alzheimer research · 2025Article
- Vagus nerve stimulation for epilepsy: A narrative review of factors predictive of response.Epilepsia · 2024Review
- Discovery of novel metabolic biomarkers in blood serum for diagnosis of Alzheimer's disease.Journal of Alzheimer's disease : JAD · 2024Article
- Plant extracts as emerging modulators of neuroinflammation and immune receptors in Alzheimer's pathogenesis.Heliyon · 2024Article
- The Inflammasome Adaptor Protein ASC in Plasma as a Biomarker of Early Cognitive Changes.International journal of molecular sciences · 2024Article
- Which neuroimaging and fluid biomarkers method is better in theranostic of Alzheimer's disease? An umbrella review.IBRO neuroscience reports · 2024Review
- A Search for New Biological Pathways in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy by Proteomic Research.Journal of clinical medicine · 2024Article
- Improvement effects of cyclic peptides fromFood science and biotechnology · 2024Article
- Research Participants' Perspectives on Precision Diagnostics for Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2024Article
- SNAP25 is a potential target for early stage Alzheimer's disease and Parkinson's disease.European journal of medical research · 2023Article
- Review
- Decreased DHA-containing phospholipids in the neocortex of dementia with Lewy bodies are associated with soluble AβBrain pathology (Zurich, Switzerland) · 2023Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
Abstract
The neurodegenerative disorder Alzheimer's disease is characterised by the formation of β-amyloid plaques and neurofibrillary tangles in the brain parenchyma, which cause synapse and neuronal loss. This leads to clinical symptoms, such as progressive memory deficits. Clinically, these pathological changes can be detected in the cerebrospinal fluid and with brain imaging, although reliable blood tests for plaque and tangle pathologies remain to be developed. Plaques and tangles often co-exist with other brain pathologies, including aggregates of transactive response DNA-binding protein 43 and Lewy bodies, but the extent to which these contribute to the severity of Alzheimer's disease is currently unknown. In this 'At a glance' article and poster, we summarise the molecular biomarkers that are being developed to detect Alzheimer's disease and its related pathologies. We also highlight the biomarkers that are currently in clinical use and include a critical appraisal of the challenges associated with applying these biomarkers for diagnostic and prognostic purposes of Alzheimer's disease and related neurodegenerative disorders, also in their prodromal clinical phases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.